Narrow search
Showing 1 - 10 of 3,478
Cover Image
The Effect of Drug Vintage on Survival : Micro Evidence from Puerto Rico's Medicaid Program
Lichtenberg, Frank R. - 2004
Using micro data on virtually all of the drugs and diseases of over 500,000 people enrolled in Puerto Rico's Medicaid program, we examine the impact of the vintage (original FDA approval year) of drugs used to treat a patient on the patient's 3-year probability of survival, controlling for...
Persistent link: https://www.econbiz.de/10012467803
Cover Image
The Expanding Pharmaceutical Arsenal in the War on Cancer
Lichtenberg, Frank R. - 2004
Only about one third of the approximately 80 drugs currently used to treat cancer had been approved when the war on cancer was declared in 1971. We assess the contribution of pharmaceutical innovation to the increase in cancer survival rates in a differences in differences' framework, by...
Persistent link: https://www.econbiz.de/10012468366
Cover Image
Secondary Pharmaceutical Patenting : A Global Perspective
Sampat, Bhaven N. - 2017
Pharmaceutical firms' use of secondary patents to extend periods of exclusivity generates concerns among policymakers worldwide. In response, some developing countries have introduced measures to curb the grant of these patents. While these measures have received considerable attention, there is...
Persistent link: https://www.econbiz.de/10012455567
Cover Image
Disease Complementarities and the Evaluation of Public Health Interventions
Dow, William H. - 1995
World Health Organization …
Persistent link: https://www.econbiz.de/10012473661
Cover Image
International Health Economics
Egan, Mark - 2013
medical innovations whose returns are earned worldwide. Because world returns drive innovation and innovation is central to … countries when governments centrally price health care. Providing world returns to medical innovation under such central pricing … benefit of medical innovation. This has the direct normative implication that medical innovations have inefficiently low world …
Persistent link: https://www.econbiz.de/10012459381
Cover Image
Pharmaceutical Pricing and R&D as a Global Public Good
Frech, Henry Edward; Pauly, Mark V.; Comanor, William S.; … - National Bureau of Economic Research - 2023
In his Labor Day address, President Biden stated that the U.S. "has the highest drug prices in the world, and there is … levels that fund and incentivize substantial research and development efforts. In contrast, in the rest of the world (ROW …
Persistent link: https://www.econbiz.de/10014287373
Cover Image
Financing Vaccines for Global Health Security
Vu, Jonathan T. - 2020
Recent outbreaks of infectious pathogens such as Zika, Ebola, and COVID-19 have underscored the need for the dependable availability of vaccines against emerging infectious diseases (EIDs). The cost and risk of R&D programs and uniquely unpredictable demand for EID vaccines have discouraged...
Persistent link: https://www.econbiz.de/10012481795
Cover Image
Does Disease Cause Vaccination? Disease Outbreaks and Vaccination Response
Oster, Emily - 2016
Childhood vaccinations are an important input to disease prevention, but vaccination rates have declined over the last decade due largely to parental fears about vaccine dangers. Education campaigns on the safety of vaccines seem to have little impact. Anecdotal evidence on disease outbreaks...
Persistent link: https://www.econbiz.de/10012456213
Cover Image
Sources of U.S. Longevity Increase, 1960-1997
Lichtenberg, Frank R. - 2002
Between 1960 and 1997, life expectancy at birth of Americans increased approximately 10% - from 69.7 to 76.5 years - and it has been estimated that the value of life extension during this period nearly equaled the gains in tangible consumption. We investigate whether an aggregate health...
Persistent link: https://www.econbiz.de/10012469960
Cover Image
'We Are Not Guinea Pigs' : The Effects of Disclosure of Medical Misconduct on Vaccine Compliance
Archibong, Belinda; Annan, Francis - National Bureau of Economic Research - 2023
In 1996, following an epidemic, Pfizer tested a new drug on 200 children in Muslim Nigeria. 11 children died while others were disabled. We study the effects of the disclosure, in 2000, of the deaths of Muslim children in the Pfizer trials on vaccine compliance among Muslim mothers. Muslim...
Persistent link: https://www.econbiz.de/10014372412